David Melamed, PhD,  —

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

Articles by

Pulmonary Artery Denervation Helps to Treat PAH, Trial Suggests

Pulmonary artery denervation was found to be safe and to improve the health of people with pulmonary arterial hypertension (PAH), according to results of an early clinical trial. The study, “Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1),” was published in the journal …

EMA Grants Priority Medicines Designation to Sotatercept for PAH

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to investigational therapy sotatercept (ACE-011) for the treatment of patients with pulmonary arterial hypertension (PAH). This designation is given to medications in development that have the potential to treat conditions with an unmet medical need…

A Conversation With Rare Disease Advocates